Applied DNA Sciences, Inc. (NASDAQ:APDN) Q4 2022 Earnings Call Transcript

James Hayward: We can do things with linear DNA that you can’t do with plasmids in terms of serving as a template. The flexibility we have with the chemistry of primers, the capacity to do unusual things like biotinylation, the fact that there is no restriction enzymes required in the processing of the RNA, the fact that we have a copy number advantage in linear DNA, have all proven motivating factors for the companies that are developing RNA drugs, both because of potential improvements in the RNA itself and in the consequent therapy and because of the opportunity for a decrease in cost and time.

Jason McCarthy: Got it. Thank you for taking the questions.

James Hayward: Thank you for asking, Jason.

Operator: Showing no further questions, this concludes our question-and-answer session. I would like to turn the conference back over to Dr. Hayward for any closing remarks.

James Hayward: Okay. Thank you, operator, and thank you to our investors and fans of the company for joining us on our call today. On behalf of the management team, the Board and all of our employees, we’re very grateful for your continuing support. We wish you the best of happy holidays and look forward to speaking with you again on our first quarter call. Thanks very much. Goodbye.

Operator: The conference has now concluded. Thank you for attending today’s presentation. You may now disconnect.